Intercorp Financial Servs Stock (NYSE: IFS)

Intercorp Financial Servs Stock (NYSE:IFS), Trade Ideas

Intercorp Financial Servs

Intercorp Financial Services Inc is a provider of financial services through banking, insurance, and wealth management businesses, as well as the recent integration of Izipay enhancing its payments ecosystem. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services, and Payments segment provides administration services, operation and processing of credit and debit cards. Its geographical segments include Peru and Panama.

bulls bears ai

Asia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Market Summary

Penny Stocks

Social Media

Rumors

Commodities

Small Cap

Global

Economics

Startups

Tech

ETFs

General

$BTC

$DOGE

AGYS

BABA

BIDU

BYON

SPDR Dow Jones Industrial Average ETF Trust

FTRE

HOOD

INCY

INTC

KWEB

MSTR

NPWR

PowerShares Golden Dragon Halter USX China Portfolio

PSFE

SFYF

STCE

STNE

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

Wall Street kicked off a data-heavy week on a mixed note as traders await key inflation updates and remarks from Fed Chair Jerome Powell in the coming days.

Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What&#39;s Driving Markets Monday?

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACIU

AMSC

AREC

ASXC

ATOS

BIIB

BNGO

CABA

CARV

CLNE

CLOV

CPSH

CTOS

ESEA

EVFM

EXFO

EXPR

FTEK

GEVO

GIII

GLMD

GMTX

GOED

HOOK

IBRX

INMB

KBSF

LEDS

LMNL

MGNX

MOSY

NAKD

NEWT

OCGN

PDSB

PIXY

PPBT

PRTA

RMED

SNDL

UONE

USCR

VCNX

VIEW

Gainers


	Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume.


60 Biggest Movers From Yesterday

Intraday Update

ACCO

ACHC

ACRE

ADIL

ADNT

ADOM

ADTN

ADUS

AFIN

AGCO

AGNC

AGRO

AIMC

AINV

ALKS

ALLY

ALTM

ALYA

AMAL

AMBC

AMCX

AMPY

ANAT

ANIK

APLS

APOG

APTV

APTX

APWC

ARCC

ARCO

ARDC

ARGO

ARNC

AROC

ASGN

ATAX

ATEN

ATKR

ATNX

ATRA

Stocks That Hit 52-Week Lows On Wednesday

Intercorp Financial Services Inc. Common Shares

Intercorp Financial Services Inc

IFS INTL HOLDINGS INC by IFS International Holdings, Inc.

IFS International Holdings Inc

Interfor Corp

INTERFIELD GBL SOFTWARE by INTERFIELD GLOBAL SOFTWARE INC.

Interfield Global Software Inc

iFAST Corp Ltd

INFRA WIRE ITA SPA ORD by Infrastrutture Wireless Italiane SPA Azioni

Infrastrutture Wireless Italiane SpA

Barclays analyst Ramsey El-Assal maintains TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) with a Equal-Weight and lowers the price target from $9 to $7.

Price Target

Analyst Ratings

TIXT

Barclays Maintains Equal-Weight on TELUS Intl, Lowers Price Target to $7

Barclays analyst Ramsey El-Assal maintains AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) with a Overweight and lowers the price target from $16 to $14.

AVDX

Barclays Maintains Overweight on AvidXchange Holdings, Lowers Price Target to $14

There is no cure for a rare blistering skin disorder called Epidermolysis Bullosa (EB), but treatments to help alleviate and control the symptoms do exist.  
The growing body of research suggests cannabinoid-based medicines can ease the pain and severe itching in those with this disorder while also improving healing.
Avicanna Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AVCN#TSX">AVCN</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTCQX">AVCNF</a>) (FSE: 0NN), a biopharma company focused on the development and commercialization of plant-derived CBD products announced it has completed a retrospective observational real-world study using its RHO Phyto branded Ultra CBD Topical Cream, an oil-based 3% CBD localized cream on patients with epidermolysis bullosa.
See also: <a href="https://www.benzinga.com/markets/cannabis/23/07/33149242/game-changer-in-epidermolysis-bullosa-treatment-cannabis-compound-holds-promise">Game-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds Promise</a>
Led by Elena Pope, MD, M.Sc., FRCPC, head of dermatology at The Hospital for Sick Children in Toronto, the study evaluated the reported and documented responses related to wound healing, pain and itch end points through images for study purposes.
The research included 20 patients with an average age of 17.3 years, including 6 female and 14 male patients. All patients were diagnosed with various subtypes of EB including dystrophic (60%), simplex (30%) and junctional (10%).
<h3 class="wp-block-heading">Results</h3>
The study findings showed that following a month-long application of the 3% CBD cream daily, 55% of patients reported improvement in wound healing while 45% displayed wound stability.
Moreover, self-reported itch and pain scores were reported in 65% and 50% of patients, respectively.
"The use of RHO Phyto branded Ultra CBD Topical Cream is a novel topical therapeutic option for EB patients, providing symptom relief and potentially aiding in wound healing with good tolerability," Dr. Pope said in a press release. "Further prospective studies are needed to substantiate these findings."
Interested in learning more about cannabis innovation? Join us at the 19th Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices go up by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.

Cannabis

Eurozone

Health Care

AVCNF

TSX:AVCN

CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment

Barclays analyst Sarah James maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Overweight and lowers the price target from $48 to $30.

PGNY

Barclays Maintains Overweight on Progyny, Lowers Price Target to $30

Barclays analyst Matthew Bouley maintains Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) with a Equal-Weight and raises the price target from $2.5 to $4.

SWIM

Barclays Maintains Equal-Weight on Latham Group, Raises Price Target to $4

Barclays analyst Matthew Bouley maintains JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) with a Equal-Weight and lowers the price target from $18 to $15.

JELD

Barclays Maintains Equal-Weight on JELD-WEN Holding, Lowers Price Target to $15

Piper Sandler&nbsp;analyst Harsh V. Kumar noted that&nbsp;last week,&nbsp;the SOX was up 2%, while the NASDAQ and S&amp;P were up 1% and 2%, respectively.&nbsp;
Starting in geopolitics, the U.S. is again&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/05/38692107/intel-qualcomm-export-licenses-revoked-by-us-tech-giants-wont-be-able-to-sell-chips-to-huawei-report" rel="noreferrer noopener">cracking down on</a>&nbsp;China&#8217;s&nbsp;Huawei Technologies Co Ltd. The government has revoked licenses to&nbsp;Intel Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and&nbsp;Qualcomm Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>).&nbsp;
Kumar noted that the move forced Intel to&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38706594" rel="noreferrer noopener">revise its quarterly revenue guidance</a>, while Qualcomm did not make any changes due to its low exposure to Huawei.&nbsp;
The analyst noted that Qualcomm only provided 4G modems and other Wi-Fi products to the company and expected product revenues to disappear by the end of the year.&nbsp;
Taiwan Semiconductor Manufacturing Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) also reported April revenues this week, which were up significantly year-on-year to&nbsp;the tune of&nbsp;~60%, Kumar flagged. He noted this&nbsp;is&nbsp;largely driven&nbsp;by leading-edge customers such as&nbsp;Nvidia Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and&nbsp;Apple Inc&nbsp;(AAPL). On Apple, the company is reportedly looking to work on implementing OpenAI&#8217;s ChatGPT into its next version of iOS.&nbsp;&nbsp;
<a target="_blank" href="https://www.benzinga.com/news/24/05/38787960/arm-holdings-gears-up-for-ai-foray-with-new-chip-division-launching-next-year" rel="noreferrer noopener">Recent reports indicated</a>&nbsp;that Arm Holdings Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) plans to commercialize its first AI chips by fall 2025.
Meanwhile, China became stricter in its retaliation to the U.S. embargo on AI chips. It canvassed its domestic tech firms, including Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), <a href="https://www.benzinga.com/government/24/05/38793179/nvidia-in-spotlight-as-chinese-tech-giants-push-for-domestic-ai-solutions">to use domestic AI chips.</a>
Photo courtesy: Shutterstock

Analyst Color

NVDA

QCOM

How Does The Semiconductor Index Trend Compare To Nasdaq? Analyst Opines

MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares are trading higher Monday after the clinical-stage biopharmaceutical company announced <a href="https://www.benzinga.com/wiim/24/05/38785384/mink-therapeutics-shares-are-trading-higher-after-the-company-announced-plans-to-sell-securities-in">private placement financing of $5.8 million.</a>
What Happened: On Monday, MiNK Therapeutics entered into a stock purchase agreement to sell securities in a private investment in public equity (PIPE) agreement. MiNK said it will sell 4.64 million shares at a price of $1.25 per share, representing a 25% premium to current prices.
The expected total of $5.8 million in financing is earmarked for accelerating the clinical trials of MiNK-215, the company&#8217;s leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein in solid tumors. The company said it&#8217;s planned to enter the clinic in early 2025. The PIPE financing agreement is expected to close on May 14, 2024.
&#8220;MiNK-215 is a novel cell therapeutic with the potential to overcome the limitations of traditional immune checkpoint inhibitors in solid tumors,&#8221; said MiNK CEO Dr. Jennifer Buell.
&#8220;Recent data highlighted MiNK-215&#8217;s activity to eradicate tumor cells in a model of MSS colorectal cancer with metastatic liver disease, a critical and growing area of unmet need. We are excited to partner with GKCC and committed to advancing our mission of reshaping the cell therapy landscape.&#8221;
Related Link: <a href="https://www.benzinga.com/insights/movers/24/05/38787064/12-health-care-stocks-moving-in-mondays-pre-market-session">12 Health Care Stocks Moving In Monday&#8217;s Pre-Market Session</a>
MiNK also announced the appointment of Yekaterina Chudnovsky as Board Observer. Chudnovsky currently serves as the chairperson of the GI Research Foundation at the University of Chicago Digestive Diseases Center, as well as on the boards of Elicio Therapeutics, Immix Biopharma, XCures and the Colorectal Cancer Alliance.
MiNK Therapeutics is scheduled to release its <a href="https://www.benzinga.com/calendars/earnings">first-quarter earnings</a> on Tuesday morning. Analysts are anticipating an EPS loss of 15 cents, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
INKT Price Action: According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, MiNK Therapeutics shares are up 11.1% at $1 at the time of publication.
Image: Pixabay.

INKT

Why MiNK Therapeutics Stock Is Up 11% Monday

Wall Street kicked off a data-heavy week on a mixed note as traders await key inflation updates and remarks from Fed Chair Jerome Powell <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38790019/april-inflation-data-preview-why-analysts-expect-economic-pressure-to-cool">in the coming days.</a>
The S&amp;P 500 remained stable, hovering around Friday&#8217;s closing levels and not far from record highs. The Nasdaq 100 rose 0.2%, poised for its third consecutive session of gains, marking the seventh positive session in the last eight.
Blue-chip stocks were also trading flat at midday, striving to extend their winning streak to the ninth consecutive day. 
The Russell 2000, tracking small-cap stocks, managed to outperform, up 0.6%. 
Treasury yields moved slightly lower, with the 10-year yield easing from 4.5% to 4.47%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 0.4%.
Animal spirits resurfaced in the meme stocks, as GameStop Inc. soared over 70% following a social media update from &#8220;Roaring Kitty,&#8221; a prominent figure in the<a href="https://www.benzinga.com/markets/equities/24/05/38787490/gamestop-shares-surge-as-roaring-kitty-resurfaces-after-3-year-silence"> 2021 meme stock phenomenon.</a>
Exchange-traded funds linked to themes like meme stocks, cryptocurrencies and high-sentiment stocks, such as the Schwab Crypto Thematic ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STCE#NYSE">STCE</a>) or the SoFi Social 50 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFYF#NYSE">SFYF</a>), saw broad-based rallies. In the cryptocurrency space, Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) outperformed peers, up over 10%, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 3.2%.
Read also: <a href="https://www.benzinga.com/general/education/24/05/38793704/who-is-roaring-kitty-why-does-his-return-to-social-media-matter-for-gamestop-stock">Who Is Roaring Kitty? Why Does His Return To Social Media Matter For GameStop Stock?</a>
Another notable market movement occurred in Chinese stocks, fueled by Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) reporting revenue that surpassed expectations, resulting in a 9.3% surge in its shares. 
The KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>) and the Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) both saw gains of 3.9% and 3.8%, respectively, ahead of a flurry of upcoming company earnings reports this week, including Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>).
In the commodities market, oil rebounded 0.8% while gold fell 1%. 
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,073.47</td>
<td>0.6%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,196.52</td>
<td>0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,220.03</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,457.14</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:38 p.m. EDT</figcaption></figure>
The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was 0.1% up to $521.20, the&nbsp;SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was flat at $395.02 and the tech-heavy&nbsp;Invesco QQQ Trust&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up 0.3% to $443.26, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.&nbsp;
Sector-wise, the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 0.8%. The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) was the major laggard, down 0.6%.
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Meme-related stocks experienced significant rallies across the board, driven by the dramatic surge in GameStop. AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) surged over 40%, Beyond Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) nearly 20%, Incyte Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) was up 7% and Bitcoin-linked MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) saw a 6% increase. Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose by 6% as well.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) gained almost 3% amid rumors of a deal with Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), with the latter poised to invest over $11 billion in a new plant in Ireland.</li>
<li>Stocks reacting to earnings included Fortrea Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) down 15%, NET Power Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) down 0.5% and Paysafe Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) up 4.2%. </li>
<li>Companies reporting earnings after the close are StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>), Intercorp Financial Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFS#NYSE">IFS</a>) and Agilysys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>). </li>
</ul>
Now read: <a href="https://www.benzinga.com/news/24/05/38789552/are-meme-stocks-back-heres-whats-going-on-with-shares-of-gamestop-amc-entertainment-koss-corp-and-mo">Are Meme Stocks Back? Here&#8217;s What&#8217;s Going On With Shares Of GameStop, AMC Entertainment, Koss Corp And More</a>
Illustration created using artificial intelligence via MidJourney.

DOGE

Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday?

MITK

N-iX To Leverage Mitek System's Technology To Offer Clients Fraud Prevention Services

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) with a Buy and raises the price target from $22 to $23.

NKTX

HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $23

Monday,&nbsp;Takeda&nbsp;Pharmaceutical Company Limited&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) and&nbsp;AC Immune SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) announced an exclusive, worldwide option and license agreement for AC Immune&#8217;s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38783373/ac-immune-and-takeda-sign-exclusive-option-and-license-agreement-for-active-immunotherapy-targetin" rel="noreferrer noopener">for Alzheimer&#8217;s disease</a>.
ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce an antibody response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer&#8217;s disease progression.&nbsp;
By inducing plaque clearance and efficiently inhibiting plaque formation in the brain, ACI-24.060 has the potential to delay or slow Alzheimer&#8217;s disease progression.&nbsp;
ACI-24.060 is&nbsp;being investigated&nbsp;in the ongoing ABATE Phase 1b/2 trial.
AC Immune will be responsible for completing the ABATE trial. Following the option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities and worldwide commercialization.
Under the terms of the agreement, AC Immune will receive an upfront payment of $100 million and be eligible to receive an option exercise fee and additional potential development, commercial, and sales-based milestones of up to approximately $2.1 billion if all related milestones&nbsp;are achieved&nbsp;over the course of&nbsp;the agreement.&nbsp;
Upon commercialization, AC Immune will&nbsp;be entitled&nbsp;to&nbsp;receive tiered double-digit royalties on worldwide net sales.
AC Immune says a total cash balance of CHF 104.8 million at the end of the first quarter plus $100 million upfront from Takeda and the anticipated ACI-35.030-related CHF 25 million milestone&nbsp;is expected&nbsp;to provide a cash&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38783554/ac-immune-reports-first-quarter-2024-financial-results-and-provides-a-corporate-update" rel="noreferrer noopener">runway for three years</a>.
Price Action: ACIU shares are up 33.8% at $3.09 at last check Monday.
Photo via Shutterstock

Biotech

Contracts

Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?

Investors with a lot of money to spend have taken a bullish stance on Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IOVA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Iovance Biotherapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $44,179, and 7, calls, for a total amount of $403,560.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $6.0 to $15.0 for Iovance Biotherapeutics over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Iovance Biotherapeutics stands at 3011.6, with a total volume reaching 5,308.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Iovance Biotherapeutics, situated within the strike price corridor from $6.0 to $15.0, throughout the last 30 days.
<h3>Iovance Biotherapeutics Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715622345_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$2.4</td>
<td>$2.1</td>
<td>$2.4</td>
<td>$11.00</td>
<td>$119.6K</td>
<td>161</td>
<td>500</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$2.7</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$11.00</td>
<td>$79.5K</td>
<td>161</td>
<td>800</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$2.45</td>
<td>$2.35</td>
<td>$2.4</td>
<td>$11.00</td>
<td>$48.0K</td>
<td>161</td>
<td>1.0K</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.25</td>
<td>$2.2</td>
<td>$2.25</td>
<td>$15.00</td>
<td>$45.0K</td>
<td>5.9K</td>
<td>535</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.35</td>
<td>$2.25</td>
<td>$2.25</td>
<td>$15.00</td>
<td>$45.0K</td>
<td>5.9K</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Iovance Biotherapeutics</h3>
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
In light of the recent options history for Iovance Biotherapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Iovance Biotherapeutics</h3>
<ul>
<li>Trading volume stands at 5,705,180, with IOVA's price down by -2.72%, positioned at $10.67.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 85 days.</li>
</ul>
<h3>What The Experts Say On Iovance Biotherapeutics</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $32.0.
<ul>
<li>Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $32.</li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Iovance Biotherapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

IOVA

Looking At Iovance Biotherapeutics's Recent Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Cameco.
Looking at options history for Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) we detected 19 trades.
If we consider the specifics of each trade, it is accurate to state that 10% of the investors opened trades with bullish expectations and 89% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $762,299 and 14, calls, for a total amount of $676,911.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $44.0 to $55.0 for Cameco over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cameco's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cameco's significant trades, within a strike price range of $44.0 to $55.0, over the past month.
<h3>Cameco Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715622340_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$0.62</td>
<td>$0.42</td>
<td>$0.56</td>
<td>$49.00</td>
<td>$577.0K</td>
<td>10.9K</td>
<td>10.1K</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$1.54</td>
<td>$1.43</td>
<td>$1.43</td>
<td>$55.00</td>
<td>$74.8K</td>
<td>6.6K</td>
<td>637</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.93</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$55.00</td>
<td>$72.2K</td>
<td>19.9K</td>
<td>4.7K</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$1.59</td>
<td>$1.43</td>
<td>$1.43</td>
<td>$55.00</td>
<td>$67.2K</td>
<td>6.6K</td>
<td>1.1K</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$5.75</td>
<td>$5.65</td>
<td>$5.75</td>
<td>$48.00</td>
<td>$58.0K</td>
<td>28</td>
<td>251</td>
</tr>
</tbody>
</table>

<h3>About Cameco</h3>
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.
Following our analysis of the options activities associated with Cameco, we pivot to a closer look at the company's own performance.
<h3>Current Position of Cameco</h3>
<ul>
<li>With a trading volume of 1,866,211, the price of CCJ is down by -2.96%, reaching $49.41.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 79 days from now.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cameco, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at Cameco's Options Market Dynamics